Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More
PM360
SEPTEMBER 21, 2023
A generic here will improve access in OAB to a product with less side effects, which is especially important in the elderly population, Casberg noted. In March, the FDA approved several new naloxone products using the pathway, including one from Amphastar, which will compete with other intranasal on the market.
105 
Let's personalize your content